Pregabalin Market Synopsis

Pregabalin Market Size Was Valued at USD 1.7 Billion in 2023, and is Projected to Reach USD 2.3 Billion by 2032, Growing at a CAGR of 3.6% From 2024-2032.

Pregabalin is an anticonvulsant drug that belongs to the class of drugs called gamma-aminobutyric acid analogs and has been mainly used for the management of neuropathic pain, epilepsy, and generalized anxiety disorder. Pregabalin belongs to the class of gabapentinoids and acts as an analogue of GABA, with anti-seizure and anti-neuropathic effects due to its ability to interact with α2δ subunits of voltage-gated calcium channels and thereby reducing the release of neurotransmitters, such as glutamate, norepinephrine, and substance P. Pregabalin is popularly sold under the name Lyrica; doctors recommend it most often for cases where other treatments are ineffective. Nevertheless, it has been seen that pregabalin is effective but has side effects which includes dizziness, somnolence, dry mouth and more over increase in weight. However, depending on the dosage used for a long time, some of the side effects include the development of a tolerance to the drug and thus need the supervision of physicians.

• Pregabalin is a sedative drug currently understood under the trademark LYRICA and it is occupied with notable market niche in the global arena especially for purposes such as neuropathic pains , epilepsy and generalized anxiety disorders . The drug was granted approval by the FDA in 2004and was soon to become a prescription medication due to the effectiveness in management of these conditions. The market for pregabalin has been strong and growing the neuropathic pain and epilepsy indication, rising size of the elderly population, and enhanced awareness of mental health disorders. In recent years, there has been a steady and constant growth rate in the market, especially with continued research and developmental work done on pregabalin to extend its use in the treatment of various medical disorders.
• However, the market of pregabalin has some problems, especially as patent protection, an important factor for the sale of this drug, has expired, and new gut less expensive analogues appeared. Nevertheless, Lyrica continues to be one of the leading drugs due to the reliability and the lack of critical side effects that were observed in clinical trials. For the silicon urea and/or ammonium nitrate produced by the firm the North America particularly the United States remains the largest market thus followed by the European and Asia-Pacific regions. Furthermore, there is more awareness being shown on forward integration where there is hope that pregabalin may be used to treat other ailments apart from the ones mentioned above thereby creating other markets that the drug can penetrate. However, risks associated with regulatory constraints, possibility of side effects linked to the drug’s extended use and demand for further surveillance of consumers are some of the storm clouds that still shape the pregabalin market.

Pregabalin Market Trend Analysis

Increasing shift towards the development and adoption of generic versions of the drug

• Many regions have recently seen the expiration of patents on branded Lyrica, which has resulted in the availability of generic pregabalin by multiple manufacturers, therefore, the prices are not as high, and the access to the medication is broader. The need for cheaper treatments is thus increasing due to the pools of consumers in different markets where individuals spend a lot in hospitals or those who barely access expensive drugs.
• It is for this reason that the effects of the spreading of generics are anticipated to keep on affecting the pregabalin market profoundly. On one hand, this trend threatens the position of brand-name Lyrica in the market; on the other, it opens up opportunities to extend its accessibility to more consumers, including those from untapped segments. Besides, enhanced cost-control measures mean that healthcare providers and insurers likewise shift to the use of generics – relying on this factor as well. Therefore, it can be expected that the overall pregabalin market will remain steady in terms of growth, where generics will significantly influence the future developments of the market.

Exploration of its potential applications beyond its current primary indications

• The market for pregabalin can thus be considered to exhibit a growing trend, due to the fact that new uses for such a drug can be sought beyond its original applications. All the current off-label applications of pregabalin are being examined based on chronic pain conditions including different chronic pain syndromes and also based on non-GAD psychiatric disorders including fibromyalgia, bipolar disorder, and major depressive disorder. Potential opportunities of expanding indications for pregabalin might create further markets for this drug and can enhance its usability in a clinical setting.
• In addition, there are steady novelties in the drug delivery systems which is a good prospects in this sphere. Subjecting pregabalin to formulation development which can include the production of an extended-release product or associating pregabalin with other analgesics or antiepileptic will boost the drug’s acceptance and effectiveness. Such innovations could result in new patents and elongate the relative commercial period of pregabalin, which would help the pharmaceutical organizations sustain market share and precipitate lucrative revenues in spite of opposition attributable to generics. These two approaches of 4 indicating an expanding range of conditions and 5 enhancing formulations can go a long way in strengthening the position of pregabalin in the market and overall utility within clinics.

Pregabalin Market Segment Analysis:

Pregabalin Market is Segmented on the basis of type, application, and distribution channel.

By Type, Tablets and Capsules segment is expected to dominate the market during the forecast period

• The market for pregabalin, based on the type of product, the tablets and capsules segment presents significant market potential for growth during the forecast period. This can be due to the general applicability, accurate measurement, and the patient preference for and comfort with OSDF over other delivery systems. It is evident that tablet and capsule products are popular for administration in hospital and over counter general use because of the easily pocketed sizes which keep patients on their prescribed dose regimen in case of diseases. Furthermore, these forms provide further standing stability and a longer life span, thus being more advantageous to the manufacturers and healthcare organizations alike. There is predictably going to be an increased use of tablets and capsules over the years due to the developments in the firming of drugs and availability of generic brands for pregabalin market in treating neuropathic pains epilepsy and other anxiety disorders.

By Application, Epilepsy segment expected to held the largest share

• In the pregabalin market, the largest segment is expected to be epilepsy, due to the effectiveness of the treatment with pregabalin in partial-onset seizures. These and other qualities make pregabalin an important weapon in the arsenal for combating epilepsy, especially for patients who are not completely satisfied with the results of traditional first-line therapy. Also, the incidence of epilepsy has gradually increased over the years, and there is also an increased awareness of the condition, leading to more diagnosis and hence more demand for antiepileptic drugs like pregabalin.
• Furthermore, the constant approval of clinical practice parameters pointing to pregabalin as an auxiliary treatment for epilepsy clearly established its presence to the market. This segment is further backed by research and development studies that are being conducted to standardize the dosage regiments of the drug and enhance the patient survival rates, which in turn is enhancing the staking of the drug in epilepsy treatment.

Pregabalin Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• Geographically, using certain assumptions, pregabalin market is expected to be dominated by the Asia-Pacific region during the forecast period due to several reasons. Neuropathic pain, epilepsy and anxiety disorders are increasingly on the rise in the region and thus the need for effective treatment options of which pregabalin has been known to be. Apart from this, there is a growing prevalence of the elderly population in the global population, especially in the Asia-Pacific region, including China, Japan, and India; therefore, the share of chronic pain patients in the global population is also increasing.
• Progressing economy in Asia-Pacific coupled with enhancement in health care facilities need of medications is enhancing the accessibility towing to unavailability of pregabalin generic in all parts of world has expanded generic pregabalin products making medications cheaper to common man. Add to that, increasing incidence of mental health and neurological diseases resulting with increased instances of pregabalin prescription rates. Altogether, these aspects lead to the conclusion that Asia-Pacific region will have leading position in the pregabalin market, indicating high participation rate in the next years.

Active Key Players in the Pregabalin Market

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Aurobindo Pharma (India)
• Lupin (India)
• Zydus Cadila (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Cipla Inc. (U.S.)
• Torrent Pharmaceuticals Ltd. (India)
• Glenmark Pharmaceuticals Limited (India)
• Medley Pharmaceuticals Ltd. (India)
• Genesis Biotec Inc. (India)
• Biomax Pharmaceutical Company (UK)
• ZCL Chemicals Ltd. (India)
• Olon S.p.A. (Italy)
• HIKAL Ltd. (India), and Other key Players

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. PREGABALIN MARKET BY TYPE (2017-2032)
   1. PREGABALIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. TABLETS AND CAPSULES
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. OTHERS
7. PREGABALIN MARKET BY APPLICATION (2017-2032)
   1. PREGABALIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. EPILEPSY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. NEUROPATHIC PAIN
   5. OTHER
8. PREGABALIN MARKET BY DISTRIBUTION CHANNEL (2017-2032)
   1. PREGABALIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITAL PHARMACIES
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. DRUG STORE AND RETAIL PHARMACIES
   5. ONLINE PROVIDERS
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. PREGABALIN Market Share By Manufacturer (2023)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. PFIZER INC. (U.S.)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. GLAXOSMITHKLINE PLC (UK)
   4. NOVARTIS AG (SWITZERLAND)
   5. MYLAN N.V. (U.S.)
   6. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
   7. SANOFI (FRANCE)
   8. F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
   9. AUROBINDO PHARMA (INDIA)
   10. LUPIN (INDIA)
   11. ZYDUS CADILA (INDIA)
   12. AMNEAL PHARMACEUTICALS LLC. (U.S.)
   13. CIPLA INC. (U.S.)
   14. TORRENT PHARMACEUTICALS LTD. (INDIA)
   15. GLENMARK PHARMACEUTICALS LIMITED (INDIA)
   16. MEDLEY PHARMACEUTICALS LTD. (INDIA)
   17. GENESIS BIOTEC INC. (INDIA)
   18. BIOMAX PHARMACEUTICAL COMPANY (UK)
   19. ZCL CHEMICALS LTD. (INDIA)
   20. OLON S.P.A. (ITALY)
   21. HIKAL LTD. (INDIA)
10. GLOBAL PREGABALIN MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Type
       4. Historic And Forecasted Market Size By Application
       5. Historic And Forecasted Market Size By Distribution Channel
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies